Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockadetherapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination

Clinical Cancer Research

Volumn 11, Issue 7, 2005, Pages 2686-2694

  Suganuma, Takayasu ^a   Ino, Kazuhiko ^a   Shibata, Kiyosumi ^a   Kajiyama, Hiroaki ^a   Nagasaka, Tetsuro ^a   Mizutani, Shigehiko ^a   Kikkawa, Fumitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; CANDESARTAN; CD34 ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CARCINOMA CELL; CARCINOMATOSIS; CONTROLLED STUDY; CYSTADENOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR GROWTH;

ADENOCARCINOMA; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIGENS, CD34; BENZIMIDAZOLES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PERITONEUM; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 17644416741     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1946     Document Type: Article

References (49)

1. McGuire III, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003;89 Suppl 3:S3-8.
2. Touyz RM, Deng L-Y, He G, Wu X-H, Schiffrin EL. Angiotensin II stimulates DNA and protein synthesis in vascular smooth muscle cells from human arteries: role of extracellular signal-regulated kinases. J Hypertens 1999;17:907-16.
3. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 2001;495:197-200.
4. +ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J Endocrinol 2002;173:315-23.
5. Nadal JA, Scicli GM, Carbini LA, Scicli AG. Angiotensin II stimulates migration of retinal microvascular pericytes: involvement of TGF-β and PDGF-BB. Am J Physiol Heart Circ Physiol 2002;282:H739-48.
6. Williams B, Baker AQ, Gallacher B, Lodwick D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995;25:913-7.
7. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998;1401:187-94.
8. Pupilli C, Lasagni L, Romagnani P, et al. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245-55.
9. Suganuma T, Ino K, Shibata K, et al. Regulation of aminopeptidase A expression in cervical carcinoma: role of tumor-stromal interaction and vascular endothelial growth factor. Lab Invest 2004;84:639-48.
10. Kikkawa F, Mizuno M, Shibata K, et al. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 2004;190:1258-63.
11. Watanabe Y, Shibata K, Kikkawa F, et al. Adipocyte-derived leucine aminopeptidase suppresses angiogenesis in human endometrial carcinoma via renin-angiotensin system. Clin Cancer Res 2003;9:6497-503.
12. 1 receptor involving protein kinase C-and mitogen-activated protein kinase-dependent signaling pathway. J Clin Endocrinol Metab 2003;88:3973-82.
13. Nielsen AH, Hagemann A, Poulsen K. The tissue renin-angiotensin system in the female reproductive tissues: a review. Adv Exp Med Biol 1995;377:253-68.
14. Vinson GP, Saridogan E, Puddefoot JR, Djahanbakhch O. Tissue renin-angiotensin system and reproduction. Hum Reprod 1997;12:651-62.
15. Yoshimura Y. The ovarian renin-angiotensin system in reproductive physiology. Front Neuroendocrinol 1997;18:247-91.
16. De Nuccio I, Salvati G, Genovesi G, et al. Physiopathology of the renin-angiotensin system in the ovary. Minerva Endocrinol 1999;24:77-81.
17. Ando H, Nagasaka T, Nomura M, et al. Premenstrual disappearance of aminopeptidase A in endometrial stromal cells around endometrial spiral arteries/arterioles during the decidual change. J Clin Endocrinol Metab 2002;87:2303-9.
18. Ito M, Itakura A, Ohno Y, et al. Possible activation of the renin-angiotensin system in the feto-placental unit in preeclampsia. J Clin Endocrinol Metab 2002;87:1871-8.
19. Ando H, Furugori K, Shibata D, Harata T, Murata Y, Mizutani S. Dual renin-angiotensin blockade therapy in patients at high risk of early ovarian hyperstimulation syndrome receiving IVF and elective embryo cryopreservation: a case series. Hum Reprod 2003;18:1219-22.
20. Inwang ER, Puddefoot JR, Brown CL, et al. Angiotensin II type 1 receptor expression in human breast tissues. Br J Cancer 1997;75:1279-83.
21. Takeda H, Kondo S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001;158:1633-7.
22. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 2002;23:348-56.
23. Egami K, Murohara T, Shimada T, et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003;112:67-75.
24. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004;90:1059-68.
25. Volpert OV, Ward WF, Lingen MW, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996;98:671-9.
26. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998;77:880-3.
27. Yoshiji H, Kuriyama S, Kawata M, et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001;7:1073-8.
28. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004;43:142-52.
29. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002;62:4176-9.
30. 1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002;294:441-7.
31. Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003;2:1139-47.
32. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
33. Brown KJ, Maynes SF, Bezos A, Maguire DJ, Ford MD, Parish CR. A novel in vitro assay for human angiogenesis. Lab Invest 1996;75:539-55.
34. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998;153:1249-56.
35. Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S. Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res 2002;62:2753-7.
36. Stimpfl M, Tong D, Fasching B, et al. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res 2002;8:2253-9.
37. Yamamoto S, Konishi I, Mandai M, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997;76:1221-7.
38. Fujimoto J, Sakaguchi H, Hirose R, Ichigo S, Tamaya T. Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma. Cancer 1998;83:2528-33.
39. Shen GH, Ghazizadeh M, Kawanami O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000;83:196-203.
40. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML, Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995;147:33-41.
41. Obermair A, Wasicky R, Kaider A, et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett 1999;138:175-82.
42. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002;55:348-59.
43. Sonmezer M, Gungor M, Ensari A, Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor β and vascular endothelial growth factor. Int J Gynecol Cancer 2004;14:82-8.
44. Kamath L, Meydani A, Foss F, Kuliopulos A. Signaling from protease-activated receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res 2001;61:5933-40.
45. Richard DE, Berra E, Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1 α in vascular smooth muscle cells. J Biol Chem 2000;275:26765-71.
46. Richard DE, Vouret-Craviari V, Pouyssegur J. Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene 2001;20:1556-62.
47. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 2004;14:123-30.
48. Muramatsu M, Katada J, Hayashi I, Majima M. Chymase as a proangiogenic factor. A possible involvement of chymase-angiotensin-dependent pathway in the hamster sponge angiogenesis model. J Biol Chem 2000;275:5545-52.
49. Sato K, Nishida N, Sasaki S, et al. Four-week oral toxicity study of TCV-116 in rats. Jpn Pharmacol Ther 1996;24 Suppl:S804.